ES2180100T3 - Agentes antitumorales de tioxantenona. - Google Patents

Agentes antitumorales de tioxantenona.

Info

Publication number
ES2180100T3
ES2180100T3 ES98113469T ES98113469T ES2180100T3 ES 2180100 T3 ES2180100 T3 ES 2180100T3 ES 98113469 T ES98113469 T ES 98113469T ES 98113469 T ES98113469 T ES 98113469T ES 2180100 T3 ES2180100 T3 ES 2180100T3
Authority
ES
Spain
Prior art keywords
hydrogen
rent
hydroxy
lower rent
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES98113469T
Other languages
English (en)
Inventor
Mark Philip Wentland
Robert Bruno Perni
Joseph William Guiles
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Sanofi Synthelabo SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Synthelabo SA filed Critical Sanofi Synthelabo SA
Application granted granted Critical
Publication of ES2180100T3 publication Critical patent/ES2180100T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms
    • C07F9/655363—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms the sulfur atom being part of a six-membered ring
    • C07F9/655372—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms the sulfur atom being part of a six-membered ring condensed with carbocyclic rings or carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D335/10—Dibenzothiopyrans; Hydrogenated dibenzothiopyrans
    • C07D335/12—Thioxanthenes
    • C07D335/14—Thioxanthenes with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 9
    • C07D335/16—Oxygen atoms, e.g. thioxanthones

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

SE DESCRIBEN COMPUESTOS QUE TIENEN UNA ACTIVIDAD ANTITUMORAL QUE TIENEN LA FORMULA EN LA QUE: (1) N ES 2 O 3 R 1 Y R 2 SON INDEPENDIENTEMENTE ALQUILO INFERIOR; Q ES UN RESIDUO SELECCIONADO ENTRE EL GRUPO QUE CONSISTE EN CH 2 NHR S UP,3 , CH 2 N(R 4 )SO 2 R 7 , CH 2 NHCHO, CH=N-AR, C(O)NR 5 R 6 , CH 2 N(R 4 )C(O)R 7 , CH 2 N(C 2 H 5 )CHO, CH 2 N(R 4 )P(O)( OALQUILO INFERIOR) 2 , CH 2 N=CH-N(R 9 )(R 10 ), CH 2 N(R 4 )C(O)CF 3 Y CH 2 N(R 4 )C(O )OR 7 ; R 3 ES HIDROGENO O ALQUILO INFERIOR; R 4 ES HIDROGENO, ALQUILO INFERIOR O AR; R 5 ES HIDROGENO, ALQUILO INFERIOR O AR; R 6 ES HIDROGENO O ALQUILO INFERIOR; R 7 ES ALQUILO INFERIOR O AR; R 8 ES HIDROXI; AR ES FENILO O FENILO SUSTITUIDO CON METILO, METOXI, HIDROXI, HALOGENO O NITRO; Y R 9 Y R 10 SON INDEPENDIENTEMENTE ALQU ILO INFERIOR; O (2) Q ES UN RESIDUO SELECCIONADO ENTRE UN GRUPO QUE CONSISTE EN CH 2 N(R 4 )SO 2 R 7 , CH=N-AR, C(O)NR 5 R 6 , CH 2 N(R 4 )C(O)R 7 , CH 2 N(R 4 P(O)(O-ALQUILO INFERIOR) 2 , CH 2 N(R4 )C(O)CF 3 Y CH 2 N(R 4 )C(O)OR 7 ; R S UP,8 ES HIDROGENO, ALQUILO INFERIOR, ALCOXI INFERIOR O HIDROXI; AR ES FENILO SUSTITUIDO CON HIDROXI Y N, R 1 , R 2 , R 5 , R 6 Y R 7 SON COMO SE HAN DEFINIDO EN LA PRESENTE ANTERIORMENTE EN LA PARTE (1) CON LA CONDICION DE QUE UNO O MAS DE R 4 , R 5 O R 7 SEA AR; O (3) Q ES UN RESIDUO SELECCIONADO ENTRE EL GRUPO QUE CONSISTE EN CH 2 N=CH-N(R 9 )(R 10 ) Y CH 2 N(R 4 )C(O)CF SUB ,3 ; R 8 ES HIDROGENO, ALQUILO INFERIOR, ALCOXI INFERIOR O HIDROXI Y N ES R 1 , R 2 , R 4 , R 7 , AR, R9 Y R 10 SON COMO SE HA DEFINIDO ANTERIORMENTE EN LA PRESENTE EN LA PARTE (1) O UNA SAL DE ADICION DE ACIDO FARMACEUTICAMENTE ACEPTABLE O UN SOLVATO DE LOS MISMOS. TAMBIEN SE DESCRIBEN LAS COMPOSICIONES QUE CONTIENEN LAS TIOXANTENONAS Y METODOS DE TRATAMIENTO DE TUMORES Y CANCER EN MAMIFEROS CON LAS TIOXANTENONAS.
ES98113469T 1993-04-08 1994-03-31 Agentes antitumorales de tioxantenona. Expired - Lifetime ES2180100T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/044,843 US5346917A (en) 1991-06-10 1993-04-08 Thioxanthenone antitumor agents

Publications (1)

Publication Number Publication Date
ES2180100T3 true ES2180100T3 (es) 2003-02-01

Family

ID=21934632

Family Applications (3)

Application Number Title Priority Date Filing Date
ES02000949T Expired - Lifetime ES2234935T3 (es) 1993-04-08 1994-03-31 Agentes antitumorales de tioxantenona.
ES94200892T Expired - Lifetime ES2134314T3 (es) 1993-04-08 1994-03-31 Agentes antitumorales de tioxantenona.
ES98113469T Expired - Lifetime ES2180100T3 (es) 1993-04-08 1994-03-31 Agentes antitumorales de tioxantenona.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
ES02000949T Expired - Lifetime ES2234935T3 (es) 1993-04-08 1994-03-31 Agentes antitumorales de tioxantenona.
ES94200892T Expired - Lifetime ES2134314T3 (es) 1993-04-08 1994-03-31 Agentes antitumorales de tioxantenona.

Country Status (24)

Country Link
US (2) US5346917A (es)
EP (3) EP1197491B1 (es)
JP (1) JPH06340655A (es)
KR (1) KR100344136B1 (es)
AT (3) ATE286043T1 (es)
AU (1) AU679717B2 (es)
CA (1) CA2120782C (es)
CZ (1) CZ289473B6 (es)
DE (3) DE69418929T2 (es)
DK (3) DK0882723T3 (es)
ES (3) ES2234935T3 (es)
FI (2) FI941638A7 (es)
GR (1) GR3030949T3 (es)
HU (1) HUT67899A (es)
IL (1) IL109241A (es)
MY (1) MY131770A (es)
NO (1) NO306947B1 (es)
NZ (1) NZ260255A (es)
PT (2) PT1197491E (es)
RU (1) RU2138495C1 (es)
SG (1) SG52765A1 (es)
SK (1) SK283799B6 (es)
TW (1) TW242623B (es)
UA (1) UA41281C2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5665760A (en) * 1995-09-18 1997-09-09 Sanofi Winthrop, Inc. Lyophilized thioxanthenone antitumor agents
US7126011B2 (en) * 2000-11-15 2006-10-24 Prom Limited Process for the preparation of thioxanthones
GB0115893D0 (en) * 2001-06-28 2001-08-22 Sanofi Synthelabo Formulations
US6747039B2 (en) * 2002-03-12 2004-06-08 Albany Molecular Research, Inc. Aza-benzothiopyranoindazoles with antitumor activity
US20030212061A1 (en) * 2002-03-12 2003-11-13 Haydar Simon N. Aza-thioxanthenones with antitumor activity
TW200510367A (en) * 2002-11-18 2005-03-16 Arqule Inc Novel lapachone compounds, their preparation, and the use thereof
US6767919B2 (en) * 2002-12-17 2004-07-27 Walker Cancer Research Institute, Inc. High specificity anticancer agents
RU2296756C2 (ru) * 2005-05-17 2007-04-10 Федеральное унитарное государственное предприятие "Государственный научно-исследовательский институт биологического приборостроения" (ГосНИИ БП) Комплексообразующие дибензосодержащие пятичленные циклические соединения, содержащие два симметричных бета-дикарбонильных заместителя с фторированными радикалами
US20080114055A1 (en) * 2006-11-10 2008-05-15 Zoltan Laboratories Llc Thioxanthone Compounds to Reverse Weight Loss
US20080207738A1 (en) * 2007-02-28 2008-08-28 Cancure Laboratories, Llc Drug combinations to treat drug resistant tumors

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3312598A (en) * 1965-06-14 1967-04-04 Sterling Drug Inc Fermentative oxidation of substituted thioxanthenes and xanthenes
US3745172A (en) * 1970-10-05 1973-07-10 Sterling Drug Inc 1-(di-(lower-alkyl)aminoalkylamino)-9-oxothioxanthenes
US4539412A (en) * 1982-07-08 1985-09-03 Rensselaer Polytechnic Institute 7-Hydroxylucanthone, 7-hydroxhycanthone and their analogs
GB8400203D0 (en) * 1984-01-05 1984-02-08 Wellcome Found Tricyclic compounds
US4582851A (en) * 1984-02-06 1986-04-15 Warner-Lambert Company Anti-bacterial 1,4-aminoalkylamino-9H-thioxanthen-9-one derivatives, compositions, and method of use therefor
US4571405A (en) * 1984-05-29 1986-02-18 Miles Laboratories, Inc. Anti-allergic chromone- or thiochromone-5-oxamic acid derivatives, compositions, and method of use therefor
AU3008289A (en) * 1988-02-22 1989-08-24 Eastman Kodak Company Novel thiorhodamines and a novel method of preparation
AU642596B2 (en) * 1991-06-10 1993-10-21 Sanofi-Synthelabo Thioxanthenone antitumor agents
US5091410A (en) * 1991-06-10 1992-02-25 Sterling Winthrop Inc. Thioxanthenone antitumor agents

Also Published As

Publication number Publication date
JPH06340655A (ja) 1994-12-13
IL109241A (en) 2001-10-31
EP1197491A1 (en) 2002-04-17
CA2120782A1 (en) 1994-10-09
DK0619315T3 (da) 1999-12-27
ES2134314T3 (es) 1999-10-01
EP0882723A1 (en) 1998-12-09
CZ289473B6 (cs) 2002-01-16
EP0619315B1 (en) 1999-06-09
PT1197491E (pt) 2005-04-29
CA2120782C (en) 2005-10-25
IL109241A0 (en) 1994-07-31
AU679717B2 (en) 1997-07-10
KR100344136B1 (ko) 2003-09-29
NO941288L (no) 1994-10-10
DE69434216D1 (de) 2005-02-03
DE69434216T2 (de) 2005-12-08
DK0882723T3 (da) 2002-11-25
FI941638L (fi) 1994-10-09
US5380749A (en) 1995-01-10
SG52765A1 (en) 1998-09-28
US5346917A (en) 1994-09-13
ATE181068T1 (de) 1999-06-15
DE69418929T2 (de) 2000-01-20
EP0882723B1 (en) 2002-07-31
FI941638A0 (fi) 1994-04-08
DE69418929D1 (de) 1999-07-15
DE69431131T2 (de) 2003-03-27
HUT67899A (en) 1995-05-29
SK39094A3 (en) 1995-07-11
ATE286043T1 (de) 2005-01-15
NZ260255A (en) 1995-07-26
ATE221524T1 (de) 2002-08-15
AU5930194A (en) 1994-10-13
DE69431131D1 (de) 2002-09-05
HU9400992D0 (en) 1994-06-28
NO941288D0 (no) 1994-04-08
FI20041691A7 (fi) 2004-12-30
EP0619315A1 (en) 1994-10-12
SK283799B6 (sk) 2004-02-03
GR3030949T3 (en) 1999-11-30
PT882723E (pt) 2002-11-29
DK1197491T3 (da) 2005-04-11
EP1197491B1 (en) 2004-12-29
ES2234935T3 (es) 2005-07-01
FI941638A7 (fi) 1994-10-09
TW242623B (es) 1995-03-11
UA41281C2 (uk) 2001-09-17
NO306947B1 (no) 2000-01-17
FI20041691L (fi) 2004-12-30
MY131770A (en) 2007-08-30
CZ74894A3 (en) 1994-11-16
RU2138495C1 (ru) 1999-09-27

Similar Documents

Publication Publication Date Title
ES2040838T3 (es) Compuestos piperazinil-heterociclicos.
ES2108425T3 (es) Analogos de atp sustituidos con n-alquilo-2.
PE52399A1 (es) Metodo para usar compuestos neurotroficos de sulfonamida
DE59308619D1 (de) Germicide wirkstoffkombinationen
LU91210I2 (fr) Emodepside & Praziquantel ainsi que leurs dérivés pharmaceutiqement acceptables (PROFENDER)
SV2002000195A (es) Compuestos farmaceuticamente activos ref. pcs10342 afae/bb
UY27952A1 (es) Nuevos derivados de benzoimidazol útiles como agentes antiproliferativos
ES2031513T3 (es) Quinazolindionas y piridopirimidinadionas.
ES2105920B1 (es) Procedimiento para preparar compuestos de benzo-y piridopiridazinona y piridazinationa.
SE8102193L (sv) Terapeutiskt aktiv organisk forening och dess anvendning
ES2028857T3 (es) Procedimiento para la preparacion de derivados de amino-tiazol y amino-oxazol.
ES2164889T3 (es) Semicarbazonas con actividad sobre el snc y preparados farmaceuticos a base de las mismas.
ES2180100T3 (es) Agentes antitumorales de tioxantenona.
ES2123873T3 (es) Pirrolocarbazol.
ES2189941T3 (es) Derivados de nucleosidos aciclicos.
DK0587499T3 (da) Benzopyranforbindelser, fremgangsmåde til deres fremstilling og deres anvendelse som cellebeskyttelsesmidler
NO931534L (no) Sulfonylbenzylsubstituerte benzo- og pyridopyridoner
ES2171911T3 (es) Poliaminas conformacionalmente restringidas y su uso como agentes antineoplasicos.
ES2164366T3 (es) Derivados de la distamicina acriloil sustituidos, procedimiento de fabricacion asociado y su utilizacion como agentes antitumorales y antivirales.
ES2090083T3 (es) Derivados de cefalosporina, procedimiento para su preparacion y composicion antimicrobiana que contiene estos derivados.
ES2094344T3 (es) Compuestos anti-virales.
AR027578A1 (es) Derivados de indano
ES8502692A1 (es) Procedimiento para la preparacion de sulfonilureas substituidas
ES2143675T3 (es) Bencenosulfonil-ureas-tioureas sustituidas, procedimiento para su preparacion, su utilizacion como medicamento o agente de diagnostico, asi como medicamento que las contiene.
ES2075976T3 (es) Derivados de aminoacido y su empleo como agentes antiviricos.